Incyte’s Phase 1 Study on INCB160058: A Potential Game-Changer in Myeloproliferative Neoplasms

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study.

Incyte Corporation is currently conducting a Phase 1 clinical study titled ‘A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.’ The study aims to evaluate the safety, tolerability, and pharmacokinetics of the drug INCB160058 in individuals diagnosed with myeloproliferative neoplasms, which include myelofibrosis, polycythemia vera, and essential thrombocythemia. This research is significant as it seeks to identify the maximum tolerated dose and recommended dose for expansion, potentially offering new therapeutic options for these conditions.

The intervention being tested is INCB160058, an oral tablet designed to treat myeloproliferative neoplasms by determining its safety and effective dosage levels. This drug is currently in the experimental phase, with participants receiving the treatment to assess its impact.

The study is interventional, employing a non-randomized, sequential intervention model with no masking. Its primary purpose is treatment-focused, aiming to establish the drug’s safety profile and optimal dosing strategy.

The study began on August 8, 2024, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on August 14, 2025, indicating ongoing recruitment and progress in the study.

The market implications of this study are noteworthy for investors. A successful outcome could bolster Incyte Corporation’s stock performance by expanding their treatment portfolio, potentially increasing market share in the myeloproliferative neoplasms segment. This development could also influence investor sentiment positively, especially if the drug shows promising results compared to competitors in the industry.

The study is currently recruiting and remains active, with further details available on the ClinicalTrials portal.